TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

aTyr Pharma, Inc. Class Action: Levi & Korsinsky Reminds aTyr Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 8, 2025 – ATYR

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Levi & Korsinsky, Llp
aTyr Pharma, Inc. Class Action: Levi & Korsinsky Reminds aTyr Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 8, 2025 – ATYR

aTyr Pharma faces a class action lawsuit alleging securities fraud related to misleading statements about its drug Efzofitimod, with stock price dropping 83.2% after announcing study did not meet primary endpoint.

Insights
DLRpJ   positive

Strong growth potential in AI and data center market, expanding capacity, increasing lease renewal rates, and estimated 3.5x capacity demand increase in next five years


ATYR   negative

Stock price dropped 83.2% after failed drug study, facing potential legal action for allegedly misleading investors about drug efficacy